What is Wedbush's Estimate for PTGX Q3 Earnings?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at Wedbush issued their Q3 2024 EPS estimates for shares of Protagonist Therapeutics in a research report issued to clients and investors on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.53) per share for the quarter. Wedbush currently has a "Outperform" rating and a $58.00 target price on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.46 per share. Wedbush also issued estimates for Protagonist Therapeutics' Q4 2024 earnings at ($0.55) EPS, FY2024 earnings at $4.15 EPS, Q1 2025 earnings at ($0.61) EPS, Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.56) EPS, FY2026 earnings at ($2.73) EPS, FY2027 earnings at ($2.20) EPS and FY2028 earnings at ($0.42) EPS.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). The company had revenue of $4.17 million for the quarter, compared to the consensus estimate of $40.00 million.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com raised shares of Protagonist Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. HC Wainwright lifted their price target on Protagonist Therapeutics from $40.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, September 12th. JMP Securities decreased their target price on Protagonist Therapeutics from $45.00 to $43.00 and set a "market outperform" rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the company an "overweight" rating in a research note on Thursday, July 25th. Finally, TD Cowen raised shares of Protagonist Therapeutics to a "strong-buy" rating in a report on Wednesday, September 25th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $53.57.

Protagonist Therapeutics Stock Up 0.0 %

Shares of NASDAQ PTGX traded up $0.01 during mid-day trading on Thursday, reaching $47.61. 427,853 shares of the company were exchanged, compared to its average volume of 735,720. The firm has a 50-day moving average of $45.47 and a 200 day moving average of $37.88. Protagonist Therapeutics has a 1 year low of $14.78 and a 1 year high of $48.89. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 18.17 and a beta of 2.17.

Insider Buying and Selling at Protagonist Therapeutics

In other news, Director William D. Waddill sold 8,000 shares of the business's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director now owns 12,000 shares of the company's stock, valued at $540,000. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director William D. Waddill sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares in the company, valued at approximately $540,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Asif Ali sold 14,203 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the transaction, the chief financial officer now directly owns 34,960 shares of the company's stock, valued at approximately $1,555,370.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.40% of the company's stock.

Institutional Trading of Protagonist Therapeutics

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Protagonist Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company's stock valued at $95,000 after purchasing an additional 379 shares during the period. GAMMA Investing LLC increased its holdings in shares of Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company's stock worth $25,000 after buying an additional 487 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in shares of Protagonist Therapeutics during the 3rd quarter valued at approximately $43,000. CWM LLC lifted its holdings in Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company's stock valued at $57,000 after acquiring an additional 1,147 shares during the last quarter. Finally, ProShare Advisors LLC grew its position in Protagonist Therapeutics by 9.2% in the first quarter. ProShare Advisors LLC now owns 14,345 shares of the company's stock worth $415,000 after acquiring an additional 1,206 shares during the period. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.